CB-11 by Cellebrain for Glioblastoma Multiforme (GBM): Likelihood of Approval

CB-11 is under clinical development by Cellebrain and currently in Phase I for Glioblastoma Multiforme (GBM).

Apex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by Health Canada | Psychedelic Invest

Apex Labs Ltd., a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, announces Health Canada Approval of the company’s secondary

June 12, 2023

Police Seizures of Psilocybin are Up 369% Since 2017 | Psychedelic Invest

As psychedelics have increased in recent years, so have the risks. Data suggests that police seizures of psychedelics, specifically psilocybin (or magic mushrooms), have surged

February 6, 2024

‘Look before you leap’: Caribou to start Ph1 autoimmune study of CAR-T therapy

Just like other cell therapy companies, Caribou Biosciences is entering the autoimmune disease field. The Berkeley, CA-based biotech disclosed Thursday afternoon that the FDA cleared

April 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.